2.1. Study design
This is a randomized, active-controlled, parallel, open-label, multicenter, phase 4, non-inferiority study conducted at 8 sites using either pregabalin SR tablets or pregabalin IR capsules. This study has been registered at Clinical Trial.gov (identifier NCT05624853).